glp-1 shortage news today 2025 The drug is over. What's next for the compounders? Why the GLP-1 Shortage Never

M., Heiner-Fokkema, M

Balances concentration with syringe precision | | 50mg | 5mL | 10mg/mL | 0.5mL (50 units) | 1.0mL (100 units) | Lower concentration improves measurement accuracy but uses solution faster | | 100mg | 2mL | 50mg/mL | 0.1mL (10 units) | 0.2mL (20 units) | Higher vial amount extends total doses but requires same precision as 50mg/1mL | | 100mg | 4mL | 25mg/mL | 0.2mL (20 units) | 0.4mL (40 units) | Optimal for multi-week protocols

As with all compounds featured in the ChoicePeps Research Library, Cagrilintide is presented for educational and scientific reference purposes only

The benefit of this is that this higher dose can be injected in one shot and the benefits of B12 supplementation may be felt sooner

Novo Nordisk owns the patent for semaglutide, meaning that compound versions of the drug are not allowed